Description: Approaches to calculating, reporting, and interpreting Tumor Mutational Burden (TMB) testing will be discussed in this second of two updates on the broader use of TMB as a potentially prognostic and predictive tool in clinical care. Dr. Stenzinger will provide an overview of how large-scale efforts to harmonize TMB measurement may bolster the potential clinical utility of TMB reporting.
Duration: 1 hr
Level of Instruction: Basic
This webinar is part 2 of a two-part series exploring the role of TMB testing in relationship to other tumor biomarkers as well as the standardization of TMB testing.
This program has been supported through an educational grant from Bristol-Myers Squibb.
Discuss the current state of TMB calculation and reporting as well as efforts to standardize this process across laboratories.
Understand the potential clinical utility of TMB and how it should be interpreted, especially in the context of other immunotherapy biomarkers.
Harness available information to improve implementation of molecularly targeted cancer diagnostics and therapies in the clinical setting.
Live Webinar Information
August 15, 2019 11:00 AM Eastern
10:00 AM Central, 9:00 AM Mountain, 8:00 AM Pacific
Add to Calendar:
Registration Time Remaining:
29 days, 22 hours
AMP Regular Member Price:
AMP Technologist Member Price:
AMP Associate Member Price:
Cookies are small pieces of information that are stored by your browser on your computerâ€™s hard drive.
You can delete or block cookies within your browser settings.
Should you opt to do this, some parts of our site may not work.
For more information, including instructions on how to remove the cookies that have been placed,